Search

Your search keyword '"HANKER, LARS"' showing total 366 results

Search Constraints

Start Over You searched for: Author "HANKER, LARS" Remove constraint Author: "HANKER, LARS"
366 results on '"HANKER, LARS"'

Search Results

1. Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease

2. Seltene Malignome der Brust

4. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

6. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

15. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

16. Seltene Malignome der Brust

17. Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

18. Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

19. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

20. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

22. TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

23. Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

25. Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study

26. #267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial

27. Latissimus dorsi flap for breast reconstruction: a large single-institution evaluation of surgical outcome and complications

28. Aszites

29. What is the evidence for lymphadenectomy in presumed early ovarian cancer?

30. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

32. Role of tumour-free margin distance for loco-regional control in vulvar cancer—a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study

33. Sorangicin A Is Active against Chlamydia in Cell Culture, Explanted Fallopian Tubes, and Topical In Vivo Treatment

34. Supplementary Figure from Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant

35. Data from Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant

36. Supplementary Tables 1-3, Figure 1 from NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas

37. Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO

38. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

41. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

42. Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1)

45. Intraoperative Sonografie zur Entfernung von nicht-palpablen und palpablen Mammakarzinomen: systematisches Review und Meta-Analyse

46. Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study

47. Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial

48. 2022-RA-420-ESGO Treatment and outcome of patients with high-grade advanced ovarian cancer (AOC) – real world data of the german quality assurance project (QS Ovar of the AGO Study Group)

50. 2022-RA-868-ESGO Risk for contralateral non sentinel metastases in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS vulva study

Catalog

Books, media, physical & digital resources